#AAD2019

Highlights AEDV

IN 77TH AAD CONGRESS

1-5 MARCH 2019

★ WASHINGTON ★

Cutaneous manifestations in systemic disease

Dra. Águeda Pulpillo Ruiz

Scientific Initiative of:

Sponsored by:

NOVARTIS

VASCULOPATHIES, HYPERCOAGULABLE STATES, AND ANTICOAGULANTS

- **Vasculopathies**

  Antiphospholipid Antibody síndrome

  Calciphilaxis

  Livedoid vasculopathy
- **Hypercoagulable Wokup**
  - Inhered thrombophilia:

    Protein C or S deficiency; antithrombin deficency; factor V Leiden; prothombin mutation
  - Accquired thrombophilia

    APLS; surgery, immobility; malignancy
  - Sistemic steroids increase risk of VTE 1.2-2X
- In general, do NOT test for inherited thrombophilia
- **Anticoagulant**

  direct oral : heparin, enoxaparin, warfarin,

  newer oral anticoagulant

  Direct thrombin inhibitor: Dabigatran, Bivalirudin, Argotraban

  Direct factor Xa inhibitor: Rivaroxaban, Apixaban, Endoxaban, Betrixaban

Thrombophilia Testing and Venous Thrombosis
N Engl J Med 2017 Sep21 377(12)1177-1187

VASCULOPATHIES, HYPERCOAGULABLE STATES, AND ANTICOAGULANTS

- **Antiphospholipid Antibody síndrome**
- Levamisole associated vasculopathy can often show positiva APLs
- Treatment

  Heparin inicial stage; Warfarin indefinite duration; Enoxaparin
- **Warfarin**
  - Treatment option in Sneddon síndrome, calcinosis cutis, livedoid vasculopathy
  - Starting doses from 2-10 mg. Target IRN 2-3
  - Drug interactions: macrolides, fluoroquinolones, azoles, griseofulvin, dapsone, cyclosporine
  - Disease associated with use: Warfarin blue toe síndrome/colesterol emboli, skin necrosis, calciphilaxis.
- **Enoxaparin**
  - Often substituted for warfarin in pregnancy.
  - Injection abdominal 1mg/kg BID, reduction in CrCl<30ml/min

VASCULOPATHIES, HYPERCOAGULABLE STATES, AND ANTICOAGULANTS

- **Calciphilaxis** 16 patients
- 11 uremic calciphilaxis: **apixaban** (factor Xa inhibitor)
- 5 non uremic calcifilaxis: dabigatran 3; rivaroxaban2
- Contraindications apixaban: severe hepatic impairment; active bleeding; risk of bleding
- Dosing 5 mg BID; 2,5 mg if age> 80y; weight<60kg; Cr>1,5
- Reversal agent: Andexanet alfa

Direct oral anticoagulant medication in calciphilaxis Brian J. King et all
International Journal of Dermatotology. Vol 50(10)1065-1070

VASCULOPATHIES, HYPERCOAGULABLE STATES, AND ANTICOAGULANTS

Livedoid vasculopathy

- **Rivaroxaban** factor Xa inhibitor
- 10 mg BID → 10mg QID
- Not Use : hepatic or renal impairment; active bleeding; risk of bleeding
- Medication contradicated: Strong CYP3A4 and P-glycoprotein inhibitors

  Ketoconazol, itraconazol, posaconazol, voriconazol

Rivaroxabanprevents painful cutaneous infartions in livedoid vasculopathy
British Journal of Dermatology 164(4):898-899;2013

POSTERS: SYSTEMIC DISEASE

- Capillary lake síndrome induced by acitretin in a patient whit pitiriasis rubra pilaris
- Capillary lake síndrome in dermatomyositis
- Alpha- beta subcutaneous panniculitis-like T-cell lymphoma with hemophagocityc síndrome
- Primary trimethylaminuria (Fish odor síndrome)

Rivaroxabanprevents painful cutaneous infartions in livedoid vasculopathy
British Journal of Dermatology 164(4):898-899;2013